Dengue vaccine is onlyrecommended in those who have previously had dengue fever. It is given as threeinjections over a year.
Statistics:
The global DengueVaccine Market is estimated to account for US$ 1,262.0 Mn in terms of valueby the end of 2027.
Global Dengue Vaccine Market:Drivers
Increasing demand for denguevaccine is expected to propel growth of the global dengue vaccine market. Forinstance, the researchers at International Vaccine Institute, South Korea,projected that around 7.8–62.9 million doses of dengue vaccine are required foronly routine vaccination of 12–23 mo cohort in first 5 years of the period2015–2022 with different vaccination schedules.
Global Dengue Vaccine Market:Opportunities
R&D of vaccines that areeffective against all age groups is expected to offer lucrative growthopportunities for players in the global dengue vaccine market. For instance, inNovember 2019, Takeda Pharmaceutical Company Limited announced that TAK-003,its dengue vaccine candidate demonstrated protection in children ages four to16 years, regardless of previous dengue exposure.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/23
Global Dengue Vaccine Market:Restraints
Dengue vaccines such as Dengvaxiaposes high risk to people without prior dengue infection. This is expected tohinder adoption of dengue vaccines, thereby hindering growth of the market.
Key Takeaways:
The Government Institutes segmentin the global dengue vaccines market was valued at US$ 169.6 Mn in 2019 and isexpected to reach US$ 657.6 by 2027 at a CAGR of 18.5% during the forecastperiod. The growth of the segmentis attributed increase in government initiatives to promote awareness andprovide vaccination facility to cope up with increasing incidence of dengue inrespective countries.
Market Trends
Major players in the market arefocused on developing recombinant subunit vaccines that are effective againstdengue. For instance, Merck is assessing the immunogenicity and safety of aninvestigational tetravalent recombinant subunit vaccine for dengue. The studycompleted phase I stage as of 2019.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/dengue-vaccines-market-23
Major players in the market arefocused on adopting M&A strategies to expand their product portfolio. Forinstance, in January 2019, Takeda Pharmaceutical Company Limited completedacquisition of Shire plc.
Global Dengue Vaccine Market:Competitive Landscape
Major players operating in theglobal dengue vaccine market include, Sanofi, Takeda Pharmaceutical CompanyLimited, GlaxoSmithKline, and Merck & Co.
Global Dengue Vaccine Market: KeyDevelopments
January 2020: Codagenix, acompany developing vaccines and viral therapies for illnesses ranging from theflu and respiratory viruses to dengue fever, raised US$ 20 million in a newround of financing
November 2019: TakedaPharmaceutical Company Limited started a plant to produce dengue vaccine inGermany
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/23
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
